You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亚盛医药(06855.HK)抑制剂Lisaftoclax之客观缓解率逾80%
阿思达克 05-20 09:31
亚盛医药(06855.HK)公布,公司四项入选2021美国临床肿瘤学会(ASCO)年会的临床研究的摘要已於今日在ASCO官网公布。这四项研究涉及公司三个细胞凋亡管线品种,含两项口头报告。

其中Bcl-2抑制剂Lisaftoclax(APG-2575)的全球I期临床研究成果显示,APG-2575治疗复发╱难治性(R/R)慢性淋巴细胞白血病╱小淋巴细胞淋巴瘤(CLL/SLL)患者的客观缓解率(ORR)达85.7%,并显示良好的耐受性与安全性。此外,MDM2抑制 Alrizomadlin(APG-115)联合帕博利珠单抗应用於经免疫肿瘤药物治疗失败的不可切除/转移性黑色素瘤或晚期实体瘤患者的II期临床研究表现出良好的前景。

数据显示,APG-115联合帕博利珠单抗治疗对PD-1/PD-L1抑制剂耐药黑色素瘤患者的疾病控制率(DCR)达60.9%,其中客观缓解率(ORR)达到17.4%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account